Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

por Østergaard, Helena Bleken, Humphreys, Valerie, Hengeveld, Ellen Margo, Honoré, Julie Broe, Mach, François, Visseren, Frank L. J., Westerink, Jan, Yadav, Gourav, Mosenzon, Ofri
Publicado 2022

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics

por Lingvay, Ildiko, Aroda, Vanita R., Honoré, Julie Broe, Ersbøll, Anne S., Nystrup Husemoen, Lise Lotte, Jensen, Anders Boeck, Sommer Matthiessen, Kasper, Kosiborod, Mikhail Naum
Publicado 2023

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

por Verma, Subodh, Bain, Stephen C., Honoré, Julie Broe, F. E. Mann, Johannes, A. Nauck, Michael, E. Pratley, Richard, Rasmussen, Søren, Sejersten Ripa, Maria, Zinman, Bernard, Buse, John B.
Publicado 2020